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ABSTRACT
The NRMD is a database for nuclear receptor
mutation information. It includes mutation informa-
tion from SWISS-PROT/TrEMBL, several web-based
mutation data resources, and data extracted from the
literature in a fully automatic manner. Because it is
also possible to add mutations manually, a hundred
mutations were added for completeness. At present,
the NRMD contains information about 893 mutations
in 54 nuclear receptors. A common numbering
scheme for all nuclear receptors eases the use of
the information for many kinds of studies. The NRMD
is freely available to academia and industry as a
stand-alone version at: www.receptors.org/NR/.
INTRODUCTION
Nuclear receptors (NRs) play a crucial role in the regulation of
gene expression, and are thus an important target for the
pharmaceutical industry. NRs consist of multiple domains,
among which are a DNA-binding domain and a ligand-binding
domain (LBD). The NRMD deals mainly with mutations in the
LBD.
Binding of hormones such as testosterone, vitamin D3 or
retinoic acid to LBDs leads to dimerization and binding of a
co-activator or co-repressor, which in turn leads to transcrip-
tion regulation. A good understanding of this process at the
molecular level is important for the pharmaceutical industry.
Mutation studies are an important source of data on the role of
individual amino acids, and together with structural data about
amino acid–ligand interactions, they play a central role in the
rational drug design process.
The function of residues in NRs is mainly determined by
their location (Folkertsma et al. in preparation; www.receptors.
org/NR/struct/alignmt.html). Therefore, a mutation of a residue
at a certain position in one receptor is likely to have a similar
effect as the mutation of a different residue at the equivalent
position in another receptor. The structural equivalence of
residue positions can thus be used to transfer information about
mutations in one NR to all other NRs. To aid this transfer of
information, we introduced a common structure-based num-
bering scheme for all NRs.
The NRMD is part of a larger project aimed at the design of
Molecular Class Specific Information Systems (MCSISs).
Well-known examples of MCSISs are the GPCRDB
(www.gpcr.org) (1) and the NucleaRDB (www.receptors.org/
NR/) (2). The NRMD currently exists as a stand-alone
mutation information resource, but full integration in the
NucleaRDB is well underway.
RESULTS
Several mutation information resources are available. SWISS-
PROT/TrEMBL (3) contain sequences of about 1300 NRs, and
from their annotation, information about 359 variants can
easily be extracted. A fully automatic search of OMIM (4) for
NR mutations is difficult, but a human-aided computer script
could extract 156 mutants from this resource. The Vitamin D
receptor (VDR) pages contain well-documented information
about vitamin D receptors. The Photoreceptor cell-specific
Nuclear Receptor pages (PNR) (5) specialize in the photo-
receptor cell-specific nuclear receptor, and the Glucocorticoid
Receptor Resource (GRR) (6) contains a lot of information
about glucocorticoid receptors. The NucleaRDB provides
point mutation data (www.receptors.org/NR/mutation/) auto-
matically extracted from the literature (Horn and Cohen, in
preparation). Using pattern matching, the method ‘MuteXt’
retrieves articles and extracts point mutations, which are then
validated by plausibility filters. These filters use the sequence
data and the in-text distances between receptor names,
organism types and mutants. The preliminary evaluation of
MuteXt yields a recall of 85%, a precision of 90% and a
coverage of 70%. The recall is the percentage of point
mutations that are correctly extracted [true positives/(true
positives þ false negatives)], the precision is the percentage of
validated point mutations that are correct [true positives/(true
positives þ false positives)] and the coverage is the percentage
of relevant point mutations that the system extracted (true and
false positives/point mutations present in the documents).
Table 1 summarizes the resources at the basis for the NRMD,
and Table 2 summarizes the information stored per mutation.
A WWW-based form gives access to a system that allows the
user to query the information. Figure 1 shows the layout of this
form.
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Table 1. Mutation information resources
Name # Mutants found Address Ref.
SWISS-PROT/TrEMBL 359 www.expasy.org 3
OMIM 156 www.ncbi.nih.gov/Omim 4
VDR 48 vdr.bu.edu
PNR 21 www.retina-international.com/sci-news/nr2e3mut.htm 5
GRR 256 nrr.georgetown.edu/GRR/mutation/mutation.html 6
MuteXta 378 www.receptors.org/NR/mutation
Manual 136
Nuclear receptor information resources. The seven tables hold the name of the resource, the number of NR mutations we found in the resource, its
location in the WWW, and the reference. Due to redundancy, the total number of mutations given by the table is not 893.
aThis is a still to be published attempt by FH to extract mutation information from electronic articles automatically, using computer programs that work
without human intervention.
Table 2. Information per mutant
Field Example Description
Mutation D351Y Mutation notation
Accession 463 Unique identifier
Pentapeptide LADRE Pentapeptide sequence with mutated
residue in third position
Link www.receptors.org/NR/mutation/D351_ESR1_HUMAN.html URL of the original mutation resource
Source NucleaRDB Name of the original resource
V/M Variant Indicates whether a mutation is a natural occurring
variant or an experimental mutagen
Receptor description ER alpha Name of the nuclear receptor
Species Homo sapiens (Human) Species name
Id P03372 SWISS-PROT accession code
Gene name NR3A1 Nuclear receptor gene name
PubMed 10815929 Link to PubMed abstract
Position in alignment 340 Residue position according to the structural alignment
Effect Cadmium did not activate mutants E523Q,
E523A, H524A, or D538N but activated E380Q . . .
Description of the observed effect of the mutant
Three columns are given. Left: the name of the data field. Middle: example of actual data stored in NRMD. Right: description. Mutations can also be
insertions, chimers, deletions, or combinations. Bibliographic information is the PubMed index. Effects include all described effects ranging from
expression pattern to antagonism, but effects are only stored if available in the original resource from which the mutation was retrieved.
Figure 1. Front page of the NRMD. Source: origin of the mutation information. Species and Receptor: obvious. Region: indicates secondary structure element in
which the mutation should reside. From, To: allow for selection of original and introduced residue type. Position allows searching for residues at a given position
using the structure-based common numbering scheme or the SWISS-PROT numbering, to choice. The top four tables are multiple selection fields. The bottom
selection field allows for searching the mutational effect fields using keywords.
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In summary, the NRMD combines NR mutation information
from all known sources. Most data collection is fully automatic
for the web-based resources so that updates will automatically
lead to an update of the NRMD. Moreover, mutation
information from the literature continues to be added manually.
To ensure high quality data, mutations are only accepted if they
are made in a sequence available from SWISS-PROT or
TrEMBL, and if the mutation is annotated correctly (i.e.
residue number, residue type, sequence name, accession code,
etc. all are the same in SWISS-PROT or TrEMBL and in the
mutation information resource). Additional information about
the NRMD is available at: www.receptors.org/NR/.
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